Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2025 15:53 ET | Source: Tevogen Bio Inc

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and...
August 11, 2025 15:45 ET | Source: Tevogen Bio Inc

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion. In...
August 11, 2025 13:24 ET | Source: Tevogen Bio Inc

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...
August 11, 2025 11:58 ET | Source: Tevogen Bio Inc

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success...
August 11, 2025 09:28 ET | Source: Tevogen Bio Inc

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, ...
August 08, 2025 11:37 ET | Source: Tevogen Bio Inc

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding...
August 07, 2025 09:00 ET | Source: Tevogen Bio Inc

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non-dilutive...
August 06, 2025 15:59 ET | Source: Tevogen Bio Inc

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

WARREN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding...
August 05, 2025 14:32 ET | Source: Tevogen Bio Inc

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and...
August 01, 2025 15:57 ET | Source: Tevogen Bio Inc

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, ...